Celebrating the great minds that bring us innovation in small molecules, biopharmaceuticals, and advanced medicine.
Gene therapies (including CAR T) could add $45 billion to US healthcare costs over the next five years, a CVS health report finds.
Let’s reduce gene therapy manufacturing costs by optimizing cell lines, improving transfectants, and optimizing downstream purification.
Sitting Down With... Miguel Forte, Chief Executive Officer at Bone Therapeutics, Belgium, to discuss advanced medicine.
Aseptic filling is the final manufacturing step but it shouldn’t be an afterthought.
UC Davis joins Orgenesis’ point-of-care network to develop and commercialize cell and gene therapies in house.
John Rossi, Director of Translational Sciences at Kite Pharma, talks about bright future of CAR T cell therapy.
Dick Sundh, Head of Europe at Kite, explains what it takes to commercialize CAR T cell therapy.
Ravi Nalliah explains his journey from biochemistry and molecular biology student, to chartered accountant, to supply chain CDMO founder.
Here we explore the challenges involved in ensuring CAR T cell therapies are delivered to patients safely and as quickly as possible.
Researchers seek a way to inactivate CAR-T cells in case of adverse effects.
Register to access our FREE online portfolio, request the magazine in print and
manage your preferences.